Jackson Acquisition Company II JACS FINANCIAL
Company Overview
Jackson Acquisition Company II does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities in the healthcare industry. The company was incorporated in 2024 and is based in Alpharetta, Georgia.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -14.6%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -14.60% |
Stock Price Performance
| 1 Year: | +4.08% |
| 6 Months: | +1.90% |
| 3 Months: | +0.85% |
| 1 Month: | +0.09% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.45 · Neutral
P/E of 36.97 is above the sector median of 12.89 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JACS Jackson Acquisition Company II FINANCIAL | 10.72 | 36.97 | $255.56M | 0.00% | -0.23% | 3.75% | - | - |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Income | -206.32K | -129.04K | -129.62K | -168.27K |
| Net Income | 2.23M | 2.32M | 2.35M | 1.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Income | -569.11K |
| Net Income | 9.12M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 234.01M | 243.18M |
| Current Assets | 1.06M | 633.06K |
| Cash & Equivalents | 949.37K | 521.78K |
| Inventory | - | - |
| Receivables | - | - |
| Total Liabilities | 357.54K | 412.31K |
| Current Liabilities | 357.54K | 412.31K |
| Long Term Debt | - | - |
| Total Debt | 198.02K | 198.02K |
| Total Equity | 233.65M | 242.76M |
| Shares Outstanding | 29.59M | 29.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -427.59K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | 3.8% |
| ROCE % | -0.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Hudson Bay Capital Management Lp | 6.38% | 1.52M | $16.38M |
| 2 | Glazer Capital LLC | 5.02% | 1.20M | $12.89M |
| 3 | Westchester Capital Management, LLC | 4.98% | 1.19M | $12.78M |
| 4 | AQR Arbitrage LLC | 4.90% | 1.17M | $12.58M |
| 5 | Linden Advisors LP | 4.82% | 1.15M | $12.39M |
| 6 | Shaw D.E. & Co., Inc. | 4.78% | 1.14M | $12.27M |
| 7 | Wolverine Asset Management, LLC | 4.40% | 1.05M | $11.29M |
| 8 | Polar Asset Management Partners Inc. | 4.30% | 1.02M | $11.04M |
| 9 | Berkley W R Corp | 3.89% | 927.84K | $10.00M |
| 10 | Mizuho Securities USA LLC | 3.80% | 905.34K | $9.75M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JACS
Understanding the Setup: (JACS) and Scalable Risk - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQTDY5QkZSbWRRb0pPVEpIOTJ1V3N3aGtrQm9pVDllckNkdGo5WS1WV3puM1Y3Qmxxd0htYjk0RVN3M2Rza2JqTi1qMG5wVjBzV0RhRmdEX29SNEpzNXdrV2c1X3g1UDR6TWp6YlNOWEl6cHdvVlRaUUpBN3pKYlNIaVpKT1FJS2NrQjItdj…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE5jRHpZUXYyeUJEN2xBT05ybGJQVzYzdjdscURHOFU2b0JIb2pkVmNJUnh4VUU5YmVhdnd4b1Rha3BLQU8ySW81eGZtZmo3cmUx?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Jackson Acquisition Company II (JACS) Holds Steady at $10.75 Amid Quiet Pre-Deal Trading - BPI Bear Correction - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPR0JVSzdhdkxaRG5pTnNTZDg5TjcyWjBYWEJLWlRVaXBKNGdWZEt4MjNBVmVFa3ZBbm00UmV1RHE5dnFTYlBVX2luSTRPMUhBZEJEekFqSGpjSmNZR2VWSV9nZkc2QVdsakRMTzBwbW9qZ213Sk53amZfYjk1U0dnd0FDTktHMmprbElNdU…
Jackson Acquisition Company II (JACS) Holds Steady at $10.75 as Investors Await Business Combination News - Bear Pennant - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOT25zbXZadkV0aS1XSUZZMmJGNVp1cHRxcm9OWk5SVEM0eWhLZndPc3VzbDJUc28zQ1NVRjhYangxY0NFZi1CdS1pTXdKalZRRUVRS2g5UHZ0MDJUSmw1eG1sYUVESWk2eTFfS2FqQy1La2d0cmpuV0xabnlRV1pTd3c5WWdURGpJZjNDa2…
JACS Stock Price and Chart — NYSE:JACS - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFB4VVNsbXRISzJuU0txZEJtQ0xsb29yUzFRV2R5ZW5TVm5HN1p2enhzamVsODhoMFg4OEEyN1Z1Z0E0UWVJc1E1ZmhUUFNURFRnaUF3Z3pLQl8tUQ?oc=5" target="_blank">JACS Stock Price and Chart — NYSE:JACS</a>&nb…
Stable Isotopic Labeling of Dimethylallyl Pyrophosphate (DMAPP) Reveals Compartmentalization of Isoprenoid Biosynthesis during Sporulation in Bacillus subtilis - ACS Publications
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQdHo1bkZtM1MzYlpacWM4LWFLSGJLMWx1WlA5QUw1LW50VGFMMHJJcGlSN1Y2SWU3ZGZ2eGN0Q3lxVndNWUVkUUZfLXJWU1d4aFZPcnFNanNBbllTVlpPN0tKd3B0ZDY4aThkZ0NQVzhrS3lURmN4NkczTURIOERRaDlBNWlsZE91WDVmVm…
JACS — Frequently Asked Questions
What is the current share price of Jackson Acquisition Company II (JACS)?
As of 2026-09-19 21:16 PDT, Jackson Acquisition Company II (JACS) trades at $10.72 on NYSE. Its 52-week range is $10.30 to $10.75.
What is the market capitalisation of JACS?
Jackson Acquisition Company II (JACS) has a market capitalisation of $255.56M on NYSE.
What is the P/E ratio of JACS?
JACS trades at a trailing price-to-earnings (P/E) ratio of 36.97. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is -2,693.75.
What is the return on equity (ROE) of JACS?
JACS has a return on equity (ROE) of 3.75%. Its return on capital employed (ROCE) is -0.23%.
Is JACS a good stock to buy?
This page provides a data-driven analysis of Jackson Acquisition Company II (JACS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.